Wait...
Search Global Export Import Trade Data
Recent Searches: No Recent Searches

Ajanta Pharma Q3 net up 25% at Rs 143 cr, denies import alert.


Date: 25-01-2017
Subject: Ajanta Pharma Q3 net up 25% at Rs 143 cr, denies import alert
Drug firm Ajanta Pharma   today reported a 25.15 percent rise in its consolidated net profit to Rs 142.60 crore for the third quarter ended December 31, 2016 mainly on account of robust sales. 

The company had posted a net profit of Rs 113.94 crore for the corresponding period of the previous fiscal, Ajanta Pharma said in a filing to BSE. 

Total income from operations of the company also rose to Rs 533.11 crore as against Rs 476.64 crore for the same period year ago. 

Commenting on the results, Ajanta Pharma Joint MD Rajesh, said: "We have posted yet another quarter of satisfactory growth in sales and profitability". 

The external factors in emerging markets continue to pose challenges resulting into sub-optimal business. However, the company has ramped up its US business which has posted great results for the quarter, he added. 

In another filing on the BSE, the company said there was no import alert on it's manufacturing unit in Aurangabad and it continues to supply to the US market. 

"There is no import alert on our facility or any of our products approved by USFDA and we continue to supply the products to US," Ajanta Pharma said. 

It appears some unknown and unrelated entity/individual has sent some Sildenafil manufactured by Ajanta Pharma being sold in India or other emerging market to US. 

"We have no relations or connection to this dispatch of Sildenafil to USA. US authorities have seized this product as it is not approved by USFDA," it added. 

The company was responding to media reports saying it has got import alert from USFDA for its Paithan unit at Aurangabad. 

The company received two abbreviated new drug application (ANDA) final approvals, commercialised 3 products and filed 6 ANDAs with USFDA during the quarter, Ajanta Pharma said. 

Shares of Ajanta Pharma today closed at Rs 1,756.50 per scrip on BSE, down 1.52 percent from its previous close. 

Source: moneycontrol.com

Get Sample Now

Which service(s) are you interested in?
 Export Data
 Import Data
 Both
 Buyers
 Suppliers
 Both
OR
 Exim Help
+


What is New?

Date: 18-09-2025
Corrigendum
Corrigendum to Notification No. 9/2025 – Central Tax (Rate) dated 17.09.2025

Date: 17-09-2025
Notification No. 13/2025-Central Tax (Rate)
Seeks to amend Notification No. 21/2018- Central Tax (Rate) dated 26.07.2018.

Date: 17-09-2025
Notification No. 14/2025-Central Tax (Rate)
Seeks to notify GST rate for bricks.

Date: 17-09-2025
Notification No. 37/ 2025-Customs
Seeks to amend Notification No.19/2019-Customs dated 06.07.2019

Date: 17-09-2025
Notification No. 38/ 2025-Customs
Seeks to amend Notification No.29/2025-Customs dated 09.05.2025

Date: 17-09-2025
Notification No. 39/2025-Customs
Seeks to amend Notification No.50/2017-Customs, dated 30.06.2017

Date: 17-09-2025
NOTIFICATIONNo. 15/2025 – Central Tax
Seeks to exempt taxpayer with annual turnover less than Rs 2 Crore from filing annual return.

Date: 17-09-2025
NOTIFICATION No. 16/2025–Central Tax
Seeks to notify clauses (ii), (iii) of section 121, section 122 to section 124 and section 126 to 134 of Finance Act, 2025 to come into force.

Date: 17-09-2025
Notification No. 12/2025-Central Tax (Rate)
Seeks to amend Notification No. 8/2018- Central Tax (Rate) dated 25.01.2018.

Date: 17-09-2025
NOTIFICATION No. 14/2025 – Central Tax
Seeks to notify category of persons under section 54(6).



Exim Guru Copyright © 1999-2025 Exim Guru. All Rights Reserved.
The information presented on the site is believed to be accurate. However, InfodriveIndia takes no legal responsibilities for the validity of the information.
Please read our Terms of Use and Privacy Policy before you use this Export Import Data Directory.

EximGuru.com

C/o InfodriveIndia Pvt Ltd
F-19, Pocket F, Okhla Phase-I
Okhla Industrial Area
New Delhi - 110020, India
Phone : 011 - 40703001